Search Results - "Huntly, B.J.P"

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 by Nangalia, J, Massie, C.E, Baxter, E.J, Nice, F.L, Gundem, G, Wedge, D.C, Avezov, E, Li, J, Kollmann, K, Kent, D.G, Aziz, A, Godfrey, A.L, Hinton, J, Martincorena, I, Van Loo, P, Jones, A.V, Guglielmelli, P, Tarpey, P, Harding, H.P, Fitzpatrick, J.D, Goudie, C.T, Ortmann, C.A, Loughran, S.J, Raine, K, Jones, D.R, Butler, A.P, Teague, J.W, O'Meara, S, McLaren, S, Bianchi, M, Silber, Y, Dimitropoulou, D, Bloxham, D, Mudie, L, Maddison, M, Robinson, B, Keohane, C, Maclean, C, Hill, K, Orchard, K, Tauro, S, Du, M.-Q, Greaves, M, Bowen, D, Huntly, B.J.P, Harrison, C.N, Cross, N.C.P, Ron, D, Vannucchi, A.M, Papaemmanuil, E, Campbell, P.J, Green, A.R

“…The authors show that the diverse mutations in CALR that occur in nonmutated JAK2 myeloproliferative diseases all introduce frameshift mutations that alter the…”
Get full text

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0 by Kiesewetter, B., Dafni, U., de Vries, E.G.E., Barriuso, J., Curigliano, G., González-Calle, V., Galotti, M., Gyawali, B., Huntly, B.J.P., Jäger, U., Latino, N.J., Malcovati, L., Oosting, S.F., Ossenkoppele, G., Piccart, M., Raderer, M., Scarfò, L., Trapani, D., Zielinski, C.C., Wester, R., Zygoura, P., Macintyre, E., Cherny, N.I.

“…The European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS) has been accepted as a robust tool to evaluate the magnitude of…”
Get full text

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia by Dawson, M A, Gudgin, E J, Horton, S J, Giotopoulos, G, Meduri, E, Robson, S, Cannizzaro, E, Osaki, H, Wiese, M, Putwain, S, Fong, C Y, Grove, C, Craig, J, Dittmann, A, Lugo, D, Jeffrey, P, Drewes, G, Lee, K, Bullinger, L, Prinjha, R K, Kouzarides, T, Vassiliou, G S, Huntly, B J P

“…Recent evidence suggests that inhibition of bromodomain and extra-terminal (BET) epigenetic readers may have clinical utility against acute myeloid leukemia…”
Get full text

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia by Giotopoulos, G, Chan, W-I, Horton, S J, Ruau, D, Gallipoli, P, Fowler, A, Crawley, C, Papaemmanuil, E, Campbell, P J, Göttgens, B, Van Deursen, J M, Cole, P A, Huntly, B J P

“…Growing evidence links abnormal epigenetic control to the development of hematological malignancies. Accordingly, inhibition of epigenetic regulators is…”
Get full text

Unrelated bone-marrow transplantation in adults by Huntly, B.J.P., Franklin, I.M., Pippard, M.J.

Get full text